Sage Mountain Advisors LLC Has $431,000 Position in Novo Nordisk A/S (NYSE:NVO)

Sage Mountain Advisors LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,168 shares of the company’s stock after purchasing an additional 202 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Novo Nordisk A/S were worth $431,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of NVO. Jennison Associates LLC boosted its stake in Novo Nordisk A/S by 100.3% in the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after purchasing an additional 11,727,507 shares in the last quarter. Polen Capital Management LLC acquired a new position in Novo Nordisk A/S in the third quarter worth $718,995,000. FMR LLC boosted its stake in Novo Nordisk A/S by 122.7% in the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after purchasing an additional 6,654,614 shares in the last quarter. Morgan Stanley boosted its stake in Novo Nordisk A/S by 96.5% in the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after purchasing an additional 4,350,862 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1 %

NYSE:NVO opened at $125.23 on Tuesday. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The business’s 50-day moving average price is $126.49 and its two-hundred day moving average price is $111.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $561.97 billion, a price-to-earnings ratio of 46.30, a PEG ratio of 2.05 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio is presently 49.17%.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. UBS Group initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.